Research programme: aurora kinase inhibitors - Vertex/Novartis
Alternative Names: VX 528Latest Information Update: 20 Jun 2007
At a glance
- Originator Vertex Pharmaceuticals
- Class
- Mechanism of Action Aurora kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 29 Jun 2004 Vertex has filed an IND with the FDA for a phase I study in cancer
- 26 Apr 2004 Data presented at the 95th Annual Meeting of the American Association for Cancer Research (AACR-2004) have been added to the Cancer pharmacodynamics section
- 28 Nov 2002 Preclinical trials in Cancer in USA (unspecified route)